VBI-002 / Virtuoso Therap - LARVOL DELTA

VBI-002, a CD47xICAM-1 bispecific antibody for the treatment of hepatocellular carcinoma, melanoma and non-small cell lung cancers (AACR 2023) - "Notably, VBI-002 is highly effective against NSCLC CDX models carrying Kras mutation and it synergizes with paclitaxel to provide additional anti-tumor activity. In conclusion, VBI-002 is a versatile novel CD47xICAM-1 bispecific antibody with potent single agent activity in various solid tumors and combined well with standard of care chemotherapies for added activity. Thus, VBI-002 warrants clinical evaluations as a single agent and in combination with standard of care chemotherapies."

Gastrointestinal Cancer • Hematological Malignancies • Hepatocellular Cancer • Lung Cancer • Lymphoma • Melanoma • Multiple Myeloma • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CD47 • ICAM1 • KRAS • SIRPA

Virtuoso Therapeutics to Present Preclinical Findings on Three Best-in-Class Bispecific and ADC Programs at the 2023 American Association for Cancer Research (AACR) Annual Meeting (PRNewswire) - "Virtuoso Therapeutics...announced that it will present three posters highlighting the preclinical data from leading bispecific antibody and ADC programs at the American Associate for Cancer Research (AACR) 2023 Annual Meeting."

Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Hematological Malignancies • Hepatocellular Cancer • Liver Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Skin Cancer • Small Cell Lung Cancer • Solid Tumor • Thoracic Cancer

CD47 x ICAM-1 bispecific antibody represents a novel approach for treating ICAM-1 overexpressing tumors (AACR 2022) - "The bispecific antibody has minimal RBC binding compared to the bivalent CD47 monoclonal antibodies and benchmark anti-CD47 antibodies. The bispecific antibody shows potent in vivo efficacy and specificity toward ICAM-1+/CD47+ positive tumor cells and represents a novel approach for treating ICAM-1+/CD47+ tumors."

Genito-urinary Cancer • Hematological Malignancies • Kidney Cancer • Lymphoma • Multiple Myeloma • Oncology • Renal Cell Carcinoma • Solid Tumor • CD47 • ICAM1 • SIRPA

Virtuoso Therapeutics to Present Preclinical Findings on Two Best-in-Class Bispecific Programs at the 2022 American Association for Cancer Research (AACR) Annual Meeting (PRNewswire) - "Virtuoso Therapeutics...announced that it will present two posters highlighting the preclinical data from leading bispecific antibody programs at the American Associate for Cancer Research (AACR) 2022 Annual Meeting....Virtuoso bispecific antibodies confer greater tumor selectivity than monoclonal antibodies. This greater selectivity allows enhanced efficacy with strong effector functions, and improved safety profile."

Preclinical • Oncology